The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Feb 21

PMID 35186992

Authors

Xuan-Zhu Chen

Zhi-Qiao Liang

Kang-Yi Yang

Kun Lv

Yao Ma

Meng-Yang Li

Hui-Juan Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: XEN gel stents are used for the treatment of open-angle glaucoma (OAG), including primary and secondary glaucoma that are uncontrolled by previous medical therapy and cases with previous failed surgery. Our aim was to systematically review of the clinical data of currently published ab-interno XEN gel stents with an emphasis on intraocular pressure (IOP), antiglaucoma medication outcomes, and safety profiles.

Methods: We analyzed all of the publications (MEDLINE, EMBASE, Cochrane Library) on the ab-interno XEN gel stent to evaluate the reduction in IOP and antiglaucoma medications following the procedure. The primary outcomes measured for the meta-analysis were reduction in IOP and anti-glaucoma medications. The secondary outcome were adverse events. For each study, we used a random effects analysis model to calculate the mean difference and 95% confidence intervals for the continuous results (reduction in IOP and antiglaucoma medications) using the inverse variance statistical method.

Results: Five hundred twenty-seven articles were checked and 56 studies were found to be relevant with a total of 4,410 eyes. There was a significant reduction in IOP as well as in the number of medications required in patients treated with ab-interno XEN implant either alone or combined with cataract surgery. This new treatment for various types of glaucoma reduced the IOP by 35% to a final average close to 15 mmHg. This reduction was accompanied by a decrease in the number of antiglaucoma medications in all the studies, approximately 2 classes of medication at the price of more needlings. The overall complete success rate was 21.0-70.8% after 2 years using strict criteria originally designed to record success rate in filtration surgery. The incidence of complications vision-threatening was low at <1%.

Conclusions: XEN gel stent was effective and safe for primary and secondary OAG. Further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation.

Citing Articles

Effectiveness and safety of the XEN45 gel stent compared to trabeculectomy in primary open-angle glaucoma: the Gold-Standard Pathway Study.

Ahmed I, Vera V, Stalmans I, Fea A, Mansouri K, Gu X BMJ Open Ophthalmol. 2025; 10(1).

PMID: 39915236 PMC: 11804186. DOI: 10.1136/bmjophth-2024-001696.

Preserflo MicroShunt Implantation: A Narrative Review of Its Standalone Benefits vs. Combined Use with Phacoemulsification in Managing Open-Angle Glaucoma.

Chilmonczyk M, Golaszewska K, Saeed E, Konopinska J Ophthalmol Ther. 2024; 14(1):41-54.

PMID: 39636489 PMC: 11724813. DOI: 10.1007/s40123-024-01068-w.

Ab-Externo XEN Gel stent implantation effectively treated refractory glaucoma with prior failed shunt tube.

Cheng A, Gupta S, Vedula G, Saddemi J, Wang V, Vartanian R BMC Ophthalmol. 2024; 24(1):384.

PMID: 39215237 PMC: 11365280. DOI: 10.1186/s12886-024-03648-7.

Complications Following XEN45 Gel Stent and Glaucoma Drainage Device Implantation During Glaucoma Fellowship.

Lentz P, Wagner I, Draper C, Ang B, Boopathiraj N, Miller D Cureus. 2024; 16(7):e65582.

PMID: 39192905 PMC: 11349036. DOI: 10.7759/cureus.65582.

Long-term effectiveness and safety of XEN45 in open-angle glaucoma patients.

Carassa R, Corsini G, Triolo G Int Ophthalmol. 2024; 44(1):310.

PMID: 38960998 DOI: 10.1007/s10792-024-03234-2.

References

Widder R, Dietlein T, Dinslage S, Kuhnrich P, Rennings C, Rossler G . The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol. 2018; 256(4):765-771. DOI: 10.1007/s00417-018-3899-7. View

Bormann C, Schmidt M, Busch C, Rehak M, Scharenberg C, Unterlauft J . Implantation of XEN After Failed Trabeculectomy: an Efficient Therapy?. Klin Monbl Augenheilkd. 2021; 239(1):86-93. DOI: 10.1055/a-1553-4547. View

Kalina A, Kalina P, Brown M . XEN Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States. Ophthalmol Ther. 2019; 8(3):435-446. PMC: 6692422. DOI: 10.1007/s40123-019-0192-8. View

Vera V, Gagne S, Myers J, Ahmed I . Surgical Approaches for Implanting Xen Gel Stent without Conjunctival Dissection. Clin Ophthalmol. 2020; 14:2361-2371. PMC: 7445523. DOI: 10.2147/OPTH.S265695. View

Schargus M, Busch C, Rehak M, Meng J, Schmidt M, Bormann C . Functional Monitoring after Trabeculectomy or XEN Microstent Implantation Using Spectral Domain Optical Coherence Tomography and Visual Field Indices-A Retrospective Comparative Cohort Study. Biology (Basel). 2021; 10(4). PMC: 8065996. DOI: 10.3390/biology10040273. View

Tan S, Walkden A, Au L . One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. Eye (Lond). 2017; 32(2):324-332. PMC: 5811690. DOI: 10.1038/eye.2017.162. View

Subasi S, Yuksel N, Ozer F, Yilmaz Tugan B, Pirhan D . A Retrospective Analysis of Safety and Efficacy of XEN 45 Microstent Combined Cataract Surgery in Open-Angle Glaucoma over 24 Months. Turk J Ophthalmol. 2021; 51(3):139-145. PMC: 8251676. DOI: 10.4274/tjo.galenos.2020.47629. View

Eraslan M, Ozcan A, Dericioglu V, Ciloglu E . Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients. Int Ophthalmol. 2021; 41(10):3371-3379. DOI: 10.1007/s10792-021-01899-7. View

Rauchegger T, Angermann R, Willeit P, Schmid E, Teuchner B . Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma. Acta Ophthalmol. 2020; 99(4):369-375. PMC: 8359400. DOI: 10.1111/aos.14627. View

10.

Fernandez-Garcia A, Zhou Y, Garcia-Alonso M, Andrango H, Poyales F, Garzon N . Comparing Medium-Term Clinical Outcomes following XEN® 45 and XEN® 63 Device Implantation. J Ophthalmol. 2020; 2020:4796548. PMC: 7125472. DOI: 10.1155/2020/4796548. View

11.

Post M, Lubinski W, Sliwiak D, Podboraczynska-Jodko K, Mularczyk M . XEN Gel Stent in the management of primary open-angle glaucoma. Doc Ophthalmol. 2020; 141(1):65-76. PMC: 7347710. DOI: 10.1007/s10633-020-09753-4. View

12.

Olgun A, Duzgun E, Yildiz A, Atmaca F, Yildiz A, Sendul S . XEN Gel Stent versus trabeculectomy: Short-term effects on corneal endothelial cells. Eur J Ophthalmol. 2020; 31(2):346-353. DOI: 10.1177/1120672120924339. View

13.

Sharpe R, Pham G, Chang P . Comparison of XEN Gelatin Stent vs Trabeculectomy with Mitomycin C: A Retrospective Study. J Curr Glaucoma Pract. 2021; 14(3):87-92. PMC: 8028032. DOI: 10.5005/jp-journals-10078-1287. View

14.

Bravetti G, Mansouri K, Gillmann K, Rao H, Mermoud A . XEN-augmented Baerveldt drainage device implantation in refractory glaucoma: 1-year outcomes. Graefes Arch Clin Exp Ophthalmol. 2020; 258(8):1787-1794. DOI: 10.1007/s00417-020-04654-3. View

15.

Gedde S, Feuer W, Lim K, Barton K, Goyal S, Ahmed I . Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2019; 127(3):333-345. DOI: 10.1016/j.ophtha.2019.10.002. View

16.

De Gregorio A, Pedrotti E, Russo L, Morselli S . Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2017; 38(3):1129-1134. DOI: 10.1007/s10792-017-0571-x. View

17.

Ozal S, Kaplaner O, Basar B, Guclu H, Ozal E . An innovation in glaucoma surgery: XEN45 gel stent implantation. Arq Bras Oftalmol. 2017; 80(6):382-385. DOI: 10.5935/0004-2749.20170093. View

18.

Gillmann K, Bravetti G, Mermoud A, Rao H, Mansouri K . XEN Gel Stent in Pseudoexfoliative Glaucoma: 2-Year Results of a Prospective Evaluation. J Glaucoma. 2019; 28(8):676-684. DOI: 10.1097/IJG.0000000000001295. View

19.

Ibanez-Munoz A, Soto-Biforcos V, Rodriguez-Vicente L, Ortega-Renedo I, Chacon-Gonzalez M, Rua-Galisteo O . XEN implant in primary and secondary open-angle glaucoma: A 12-month retrospective study. Eur J Ophthalmol. 2019; 30(5):1034-1041. DOI: 10.1177/1120672119845226. View

20.

Reitsamer H, Sng C, Vera V, Lenzhofer M, Barton K, Stalmans I . Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019; 257(5):983-996. DOI: 10.1007/s00417-019-04251-z. View